Related Experiment Video
Updated: Sep 3, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Interferon-gamma in multiple myeloma
A Palumbo1, B Bruno, M Boccadoro
1Dipartimento di Medicina e Oncologia Sperimentale, Università di Torino, Ospedale Molinette, Italy.
Insights
Interferon-gamma (IFN-gamma) effectively inhibits multiple myeloma cell proliferation by targeting the key growth factor, Interleukin-6 (IL-6). This finding supports further in vivo studies for potential new cancer therapies.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Multiple myeloma exhibits biological heterogeneity, influenced by a complex cytokine network.
- Cytokines play a crucial role in regulating plasma cell growth and tumor progression in multiple myeloma.
- Interleukin-6 (IL-6) is recognized as a central growth factor for myeloma cells.
Purpose of the Study:
- To investigate the antiproliferative effects of Interferon-gamma (IFN-gamma) on multiple myeloma cells.
- To explore the mechanism of IFN-gamma's action, particularly its impact on IL-6 signaling.
- To compare the efficacy of IFN-gamma with other agents like Interferon-alpha (IFN-alpha) and dexamethasone (DEX).
Main Methods:
- In vitro proliferation assays using IL-6 dependent and independent myeloma cell lines.
- Assessment of IFN-gamma's effect on fresh explanted bone marrow myeloma cells.
- Evaluation of immunoglobulin (Ig) secretion and potential differentiating activity.
Main Results:
- IFN-gamma demonstrated potent inhibition of myeloma cell proliferation, comparable to dexamethasone (DEX).
- The antiproliferative effect of IFN-gamma was primarily attributed to the inhibition of IL-6.
- IFN-alpha inhibited Ig secretion, while combined interferons (IFNs) affected both proliferation and Ig synthesis, mirroring DEX effects.
- IFN-gamma also showed potential differentiating activity, augmenting monoclonal immunoglobulin secretion in some cases.
Conclusions:
- IFN-gamma exhibits significant in vitro antitumor activity against multiple myeloma cells.
- The inhibition of IL-6 is a key mechanism underlying IFN-gamma's antiproliferative effects.
- These findings provide a strong rationale for evaluating the in vivo therapeutic potential of IFN-gamma in multiple myeloma.
Abstract:
Biological heterogeneity is a characteristic of multiple myeloma. A dysregulated cytokine network underlies the various phases of the disease. Numerous cytokines, either promoting or inhibiting plasma cell growth, are involved in tumor control. Interferon-gamma (IFN-gamma) showed the most powerful inhibiting activity on myeloma cell proliferation. This effect was demonstrated on IL-6 dependent myeloma cell lines, but not on IL-6 independent ones. It was also evident on fresh explanted bone marrow myeloma cells. The antiproliferative effect of IFN-gamma seems mainly due to the inhibition of IL-6, the central myeloma growth factor. IL-6 inhibition may occur at various levels: a downregulation of IL-6 receptor has been reported, and also a block of the IL-6 signal transduction pathway via interaction with cytoplasmic proteins such as p91 has been suggested. Our findings showed that IFN-gamma strongly inhibited myeloma cell proliferation to the same extent as dexamethasone (DEX), whereas interferon-alpha (IFN-alpha) inhibited Ig secretion. The combined use of interferons (IFNs) showed inhibitory activities both on proliferation and Ig synthesis that paralleled the effects of DEX. In some cases, IFN-gamma was also shown to augment monoclonal immunoglobulin secretion suggesting a possible differentiating activity on plasma cells. The in vitro data encouraged pilot studies to evaluate the in vivo antitumor effects of IFN-gamma.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Tumor Immunotherapy
Inhibitors of Viral Protein Synthesis

